TP53 and rhabdoid tumor: This is also supported by a recent report that utilized a CRISPR screen in rhabdoid sarcoma and merkel cell carcinoma models and found RB1 or TP53 loss as a mediator of resistance to EZH2 inhibition (46, 53).